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ABSTRACT 
Objective: This study sought to preliminarily investigate the inhibitory effect of metabolites of Aspergillus chevalieri and Trichoderma harzianum on 
a number of pathogenic bacteria. 
Methods: The agar well diffusion method was employed to determine the antimicrobial activity of the fungal metabolites. The test microorganisms 
were Enterococcus faecalis, methicillin-resistant Staphylococcus aureus (MRSA), Salmonella typhi, Escherichia coli and Pseudomonas aeruginosa.  
Results: Both metabolites had broad-spectrum antibacterial activity. All the test organisms were susceptible to the A. chevalieri metabolites except for S. 
typhi. Both S. typhi and E. faecalis were however not susceptible to T. harzianum metabolites. P. aeruginosa was highly susceptible to both metabolites 
with the highest zone of inhibition of 26 mm for the stock metabolite. This activity was comparable to the standard, 10 µg/ml of ciprofloxacin. 
Conclusion: Metabolites of A. chevalieri and T. harzianum exhibited broad-spectrum activity, and this can be exploited as a source for novel antibiotics. 
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INTRODUCTION 
Infectious diseases caused by bacteria, fungi, and protozoa are 
common and widespread. They are the primary causes of morbidity, 
mortality, and a social and economic hindrance for millions of 
people [1]. According to the World Health Organization (WHO), over 
9.5 million people die yearly due to infectious diseases [2]. The rapid 
emergence of resistant microbial strains has even more so greatly 
endangered the efficacy of existing antibiotics [3], coupled with the 
slow rate drug development, the world is unable to keep up with the 
fight against resistant microbial strains [4]. Worldwide, the 
emergence of antimicrobial-resistant bacterial strains is increasingly 
limiting the potency of current drugs, and significantly causing 
treatment failures [5, 6]. This has necessitated the fervent need to 
search for new antibiotics from natural products [7, 8]. Fungi were 
among the first sources of antibiotics [9] known to man. The 
discovery and development of the penicillins and cephalosporins 
from fungal sources, till date, remains some of the most important 
antibiotics [10] to humankind. 
The Fungi Kingdom is the second largest [11] in species, and its 
members frequently employ the technique of antibiosis in 
combating bacteria. Antibiosis is the inhibition of one 
microorganism by the metabolic product of another. The metabolite 
penetrates the cell and inhibits it by chemical toxicity [12]. Fungi are 
a rich source of several bioactive compounds, including antibiotics 
[11]. In that respect, the fungi, Trichoderma harzianum and 
Aspergillus chevalieri, which are widely available and whose related 
species are widely known to have the ability to exhibit antibiosis 
were chosen.  
A. chevalieri, belongs to the family Trichocomaceae. It is a storage 
mould affecting the germination of grains [13]. Invasion of such stored 
grains is under both hermetic and non-hermetic conditions [14]. A. 
chevalieri is known for its ability to grow at extremely low water 
activities [15]. In humans, A. chevalieri is an opportunistic pathogen 
which causes skin infections [16]. Aspergillus species on the other 
hand, are ubiquitous molds [17], being the most prevalent fungi 
present in all soils. Many species in this genus are characterized as 
opportunistic avirulent plant symbionts [18]. Several strains of 
Trichoderma such as T. harzianum, T. viride and T. hamatum have been 
developed as biocontrol agents against fungal diseases of plants [19]. 
Trichoderma species are also known to exhibit antimicrobial activity 
against a significant number of bacteria, yeasts, and filamentous fungi 
[20]. These species release antibiotics and other chemicals that are 
harmful to pathogens. The aim of this study was to therefore evaluate 
the inhibitory effect of metabolites of A. chevalieri and T. harzianum on 
a number of pathogenic bacteria. 
MATERIALS AND METHODS 
Chemicals and reagents  
Potato Dextrose Broth (PDB), Nutrient agar and Nutrient Broth with 
reference ciprofloxacin, were all obtained from (Oxoid Limited, UK). 
All other reagents were obtained from standard suppliers. 
Culture metabolite preparation 
To obtain the culture metabolites of Aspergillus chevalieri, and 
Trichoderma harzianum, 3 cm agar disc of these fungi was inoculated 
into separate 500 ml Erlenmeyer flask containing 250 ml of sterile 
Potato Dextrose Broth (PDB). They were prepared in triplicates for each 
of the test fungi. These were incubated at room temperature for 7 d. The 
medium was then filtered by suction and pooled together. The collected 
filtrate was further filtered through a sterile Acrodisc® Millipore filter 
0.2 μm (Gelman Sciences, USA). This served as the stock.  
Test organisms 
The bacteria and fungi used for the experiments were obtained from the 
Department of Pharmaceutics and Microbiology of the School of 
Pharmacy (UGSOP), University of Ghana. The gram-positive bacteria 
employed in this study were Enterococcus faecalis and methicillin-
resistant Staphylococcus aureus (MRSA). The gram-negative bacteria 
employed were Salmonella typhi, Escherichia coli, and Pseudomonas 
aeruginosa. 
Preparation of test solutions 
The undiluted filtrate served as the stock, from which different 
dilutions were made. This was done by performing serial dilutions of 
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2 ml of the stock solution with 2 ml of sterile Millipore water in 
sterile 6 well plates. The final test solutions were the stock, 1 in 2 
dilution, 1 in 4 dilution, and 1 in 8 dilution. 
Antibacterial activity determination 
The antibacterial activity was evaluated using the agar well diffusion 
method [21]. Twenty millilitres of sterile molten nutrient agar, 
stabilized at 45 °C for 15 min were seeded with 50 μl  of a 24 hour 
culture of test bacteria, and aseptically poured into a sterile petri 
dish and allowed to set. The bacteria and fungi cultures were 
standardized to a 0.5 McFarland tube. Four wells (8 mm in diameter) 
equidistant from each other were created with a sterile cork borer 
(number 5). The wells were then filled with 100 µl  of the stock, 1 in 
2, 1 in 4, and 1 in 8 dilutions of the fungal metabolites. The plates 
were pre-incubated for 30 min at room temperature. This was to 
allow diffusion of the metabolites. The plates were then further 
incubated at 37 °C for 24 h [22, 23]. Reference antibiotic, 
ciprofloxacin (10 µg/ml) was used as the control. The procedure was 
performed in it triplicates and the mean zones of growth inhibition 
were determined.  
RESULTS 
The metabolites from A. chevalieri inhibited the growth of S. typhi, 
and P. aeruginosa up to the 1 in 4 dilution. The higher concentration 
of 1 in 2 dilution of this same metabolite demonstrated activity 
against MRSA and E. facecalis. No activity was seen against S. typhi in 
the concentrated extract. The 1 in 8 dilution of T. harzianum 
metabolite was active against E. coli and P. aeruginosa, while activity 
was seen against MRSA up to the 1 in 4 dilution, however this 
metabolite was neither active against S. typhi nor E. faecalis. The 
culture metabolites of A. chevalieri and T. harzianum had broad-
spectrum antimicrobial activity against both Gram positive and 
Gram negative bacteria. That of T. harzianum metabolites was more 
active at the highest dilution of 1 in 8 than A. chevalieri metabolites. 
Detailed results are displayed in tables 1 and 2. Fig. 1 is the growth 
of the two fungi under investigation, on potato dextrose agar. 
  
 
Fig. 1: Aspergillus chevalieri and Trichoderma harzianum on potato dextrose agar 
 
Table 1: Antimicrobial activity of A. chevalieri 
Test organism Dilutions Zone of inhibition (mm) Ciprofloxacin (10 µg/ml) 
E. coli Stock  19.33±2.31 38±1.9 
 1in 2 17.00±1.00  
 1in 4 13.00±0.00  
Ps. aeruginosa Stock 25.50±2.12 28±3.8 
 1 in 2 21.50±0.71  
 1 in 4 16.00±0.00  
S. typhi Stock  




MRSA Stock  18.67±1.53 37±2.0 
 1 in 2 13.33±1.15  
E. faecalis Stock  19.00±0.00 24±3.2 
 1 in 2 17.00±0.00  
n=3, data given is mean±SEM 
 
Table 1: Antimicrobial activity of T. harzianum 
Test organism Dilutions Zone of inhibition (mm) Ciprofloxacin (10 µg/ml) 
E. coli Stock  27.00±2.65 38±1.7 
 1 in 2 22.33±4.04  
 1 in 4 20.00±0.00  
 1 in 8 15.00±0.00  
Ps. aeruginosa Stock  27.50±2.12 28±3.0 
 1 in 2 25.00±2.83  
 1 in 4 21.50±0.71  
 1 in 8 16.00±0.00  
S. typhi Stock  




MRSA Stock  24.33 37±2.5 
 1 in 2 19.33  
 1 in 4 15.00  
E. faecalis Stock  




n=3, data given is mean±SEM 
Bekoe et al. 




Increasing levels of multidrug resistant microorganisms, coupled 
with the slow rate of drug development has led to the dire need for 
new antibiotics [24]. Natural products are known to be rich sources 
of antimicrobial drugs. They account for over two-thirds of clinically 
important antibiotics and half of anticancer medicines in use [25]. 
The inhibition of the pathogenic organism’s P. aeruginosa, MRSA, E. 
coli and E. facecalis is indicative of the presence of antimicrobially 
active compounds in these metabolites. The synthesis of 
antimicrobial compounds by fungal strains is a well-known 
phenomenon. Fungi strains are known to produce secondary 
metabolites that aid their virulence and survival against other 
microorganism [26]. A. chevalieri metabolites inhibited both Gram 
positive and Gram negative bacteria, hence it can be described as 
having broad spectrum antibacterial activity. These results agrees 
with previous reports that Aspergillus species are widely known to 
produce antibiotics. The antibiotics produced are components of the 
metabolites and are capable of inhibiting the growth of other 
microorganisms [11]. Aspergillic acid, penicillic acid and fumagillin 
[17] are well-known examples of such antibiotics. The metabolites 
showed significant activity against P. aeruginosa which was 
comparable to ciprofloxacin, the reference antibiotic. P. aeruginosa is 
one of the multidrug-resistant bacteria which is hard to treat. P. 
aeruginosa is known to have resistance to intermediate 
susceptibility to at least one antibiotic. This high level of resistance is 
attributable to the multiple intrinsic resistance mechanisms that P. 
aeruginosa may express, which include beta-lactamase production, 
efflux-mediated and porin-related resistance, and target site 
modification [24]. These mechanisms are often present in 
combination, causing a broad range of antibiotics to be rendered 
ineffective against a given P. aeruginosa isolate [27]. In that respect, 
these fungal metabolites can therefore be exploited to develop new 
antibiotics. T. harzianum metabolites also inhibited the growth of E. 
coli. P. aeruginosa, MRSA but not E. faecalis and S. typhi. These results 
are in accordance with other published data [18, 19, 28]. The 
suggested mechanisms for biocontrol of Trichoderma species of 
plant pathogens include antibiosis, lysis, competition, and 
mycoparasitism [29]. Trichoderma species are also known to exhibit 
antimicrobial activity against a significant number of bacteria, 
yeasts, and filamentous fungi [20]. These species release antibiotics 
and other chemicals that are harmful to pathogens through 
antibiosis.  
CONCLUSION  
In conclusion, Aspergillus chevalieri and Trichoderma harzianum 
metabolites have good antimicrobial activity against the bacteria E. 
coli, Ps. Aeruginosa and MRSA. This preliminary results indicates that 
these fungal metabolites contain antimicrobially active compounds 
that can be exploited for antibiotic production, and development. 
Further studies to elucidate the antibacterial active compounds can 
be initiated in that respect. 
ACKNOWLEDGEMENT 
The authors will like to thank Mr. Clement Sasu and Mrs. Akosua 
Okraku of the Department of Pharmaceutics and Microbiology, all of 
the University of Ghana, for their technical assistance when 




Both EOB and MW-K contributed equally to this study. JG was 
responsible for conducting the antimicrobial studies. All authors 
read and approved the manuscript. 
CONFLICT OF INTERESTS 
None 
REFERENCES 
1. Gao J, Radwan MM, Leon F, Wang X, Jacob MR, Tekwani BL, et 
al. Antimicrobial and antiprotozoal activities of secondary 
metabolites from the fungus Eurotium repens. Med Chem Res 
2012;21:3080–6. 
2. Peleg AY, Hooper DC. Hospital-acquired infections due to gram-
negative bacteria. N Engl J Med 2010;362:1804–13. 
3. Golkar Z, Bagasra O, Pace DG. Bacteriophage therapy: a 
potential solution for the antibiotic resistance crisis. J Infect 
Dev Ctries 2014;8:129–36. 
4. Smith R. The true cost of antimicrobial resistance. Br Med J 
2013;346:f1493. 
5. Hancock REW. Mechanisms of action of newer antibiotics for 
gram-positive pathogens. Lancet Infect Dis 2005;5:209–18. 
6. Bonjar GHS, Fooladi MH, Mahdavi MJ, Shahghasi A. 
Broadspectrim, a novel antibacterial from streptomyces sp. 
Biotechnology 2005;3:126–30. 
7. Bosgelmez Tinaz G. Disruption of bacterial cell-to-cell 
communication (Quorum Sensing): a promising novel way to 
combat bacteria-mediated diseases. J Marmara Uni Instit 
Health Sci 2013;3:1. 
8. Zgoda JR, Porter JR. A convenient microdilution method for 
screening natural products against bacteria and fungi. Pharm 
Biol 2001;39:221–5. 
9. Clardy J, Fischbach MA, Currie CR. The natural history of 
antibiotics. Curr Biol 2009;19:437-41. 
10. Karwehl S, Stadler M. Exploitation of fungal biodiversity for 
discovery of novel antibiotics. Curr Top Microbiol 
2016;398:303–38. 
11. Majolagbe ON, Aina DA, Omomowo IO, Thomas A. 
Antimicrobial potentials of soil fungi metabolites, molecular 
dynamics and their 3d protein structural prediction using 
bioinformatics tool. IJCPR 2020;12:20-6. 
12. Wiafe Kwagyan M, Odamtten GT, Obodai M. Possible 
antibiosis effect of the metabolites of three fungal species 
resident in rice straw and husk compost on the in vitro radial 
and vegetative growth by pleurotus ostreatus strain EM-1 
and P. eous strain P-31. Int J Curr Microbiol Appl Sci 
2015;4:525-38. 
13. Abu AA, Ado SA, James DB. Raw starch degrading amylase 
production by mixed culture of aspergillus niger and 
saccharomyces cerevisae grown on sorghum pomace. Afr J 
Biotechnol 2005;4:785–90. 
14. Ajayi AA, Adejuwon AO, Obasi CK, Olutiola PO, Peter Albert CF. 
Amylase activity in culture filtrate of aspergillus chevalieri. 
IJBCS 2014;8:2174–82. 
15. Chen AJ, Hubka V, Frisvad JC, Visagie CM, Houbraken J, Meijer 
M, et al. Polyphasic taxonomy of Aspergillus (formerly 
Eurotium), and its occurrence in indoor environments and 
food. Stud Mycol 2017;88:37–135. 
16. Naidu J, Singh SM. Aspergillus chevalieri (Mangin) thom and 
church: a new opportunistic pathogen of human cutaneous 
aspergillosis: Aspergillus chevalieri (Mangin) Thorn und 
Church: Ein neuer opportunistischer erreger von kutaner. 
Aspergillose Beim Menschen Mycoses 1994;37:271–4. 
17. Bramki A, Ghorri S, Jaouani A, Dehimat L, Kacem CN. 
Antibacterial activity of aspergillus isolated from different 
algerian ecosystems. Afr J Biotechnol 2017;16:1699–704. 
18. Leelavathi MS, Vani L, Reena P. Antimicrobial activity of 
Trichoderma harzianum against bacteria and fungi. Int J Curr 
Microbiol Appl Sci 2014;3:96–103. 
19. Kucey RMN, Janzen HH, Leggett ME. Microbially mediated 
increases in plant-available phosphorus. Adv Agron 
1989;42:199–228. 
20. Hermosa R, Cardoza RE, Rubio MB, Gutierrez S, Monte E. 
Secondary metabolism and antimicrobial metabolites of 
trichoderma. Biotechnology and Biology of Trichoderma; 2014. p. 
125-37. 
21. Agyare C, Bempah SB, Boakye YD, Ayande PG, Adarkwa Yiadom 
M, Mensah KB. Evaluation of antimicrobial and wound healing 
potential of Justicia flava and Lannea welwitschii. Evid Based 
Complement Alternat Med 2013;2013:1-0. 
22. Agyare C, Koffuor GA, Boamah VE, Adu F, Mensah KB, Adu-
Amoah L. Antimicrobial and anti-inflammatory activities of 
Pterygota macrocarpa and Cola gigantea (Sterculiaceae). Evid 
Based Complementary Altern Med 2012:1-9. https://doi.org/ 
10.1155/2012/902394. 
Bekoe et al. 
Int J Pharm Pharm Sci, Vol 13, Issue 2, 67-70 
 
70 
23. Gbedema SY, Emelia K, Francis A, Kofi A, Eric W. Wound healing 
properties and kill kinetics of Clerodendron splendens G. Don, a 
Ghanaian wound healing plant. Pharmacogn Res 2010;2:63-8. 
24. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad 
bugs: confronting the challenges of antibacterial discovery. Nat 
Rev Drug Discovery 2007;6:29–40. 
25. Newman DJ, Cragg GM. Natural products as sources of new 
drugs over the 30 y from 1981 to 2010. J Nat Prod 
2012;75:311–35. 
26. Jakubczyk D, Dussart F. Selected fungal natural products with 
antimicrobial properties. Molecules 2020;25:911. 
27. Nguyen L, Garcia J, Gruenberg K, MacDougall C. Multidrug-
resistant pseudomonas infections: hard to treat, but hope on 
the horizon? Curr Infect Dis Rep 2018;20:23. 
28. Khayat AS, Al-Aaraji AM. The inhibitory effect of trichoderma 
crude extract against some human pathogenic bacteria. Plant 
Arch 2020;20:627–32. 
29. Cook R, Baker KF. The nature and practice of biological control 
of plant pathogens. Am Phytopathol Soc 1983;2:539. 
 
